| Name | Title | Contact Details |
|---|---|---|
Elana Hansen |
Chief Financial Officer | Profile |
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
A Global Development Expedition FOR women, not ABOUT women. Signature Leaders is designed to augment, rather than replace, existing corporate executive leadership development. These are programs for women with the highest potential, to fast-track them into next level leadership. These women are managing large P&Ls, leading transformations across the enterprise or sizeable functional teams, or in that critical "pivot" from managing to leading. We gather these elite leaders from around the world for introspective learning and external connections. Our executive faculty covers our framework of Who You Are, How You Show Up, and How You Relate to Others. Unlike typical seminars or conferences, participants will join the Signature community upon enrollment. This means the opportunities for learning and growth starts prior to, and continues beyond, the immersion session. Signature alumni move forward with an invaluable network of more than 2,300 peers and 250 executive faculty members and advisors who support them throughout their ongoing leadership journey. Why Signature as a name? Because every executive has a unique style and "signature" embedded in the way they lead. Our curriculum focuses on the essential capabilities needed for next level leadership in a way that encourages executives to broaden, not change their own distinct style – the leadership signature that makes them authentic.
You can count on Rushlight Ventures to maximize the value of your intellectual property (IP). Rushlight Ventures is a leading venture studio that specializes in the monetization of defense and dual-use intellectual property created by small and mid-sized businesses conducting federally sponsored research. We are both "IP type" and "monetization path" agnostic. We can pursue value creation from your IP via licenses, asset sales, startups, joint ventures, M&A, or internal business units. We work with IP of all varieties, including products, patents, trade secrets, proprietary relationships, and know-how. At Rushlight Ventures, we provide a range of consulting and support services, including: • Licensing • Asset sales • Joint ventures • Startup and spin-out creation • Commercialization planning and TABA support Companies primarily focused on delivering high-quality research, development, testing, and evaluation services (RDT&E) and other large programs may find it challenging to be equally adept at technology commercialization. Thats why Rushlight Ventures (RLV) originated as a venture studio in 2020 within Cornerstone Research Group (CRG), its sister company and a renowned government contractor for more than 25 years. Soon after forming the venture studio, leadership realized that CRG was not the only company grappling with transition and monetization difficulties, and RLV was spun off as an independent entity in 2021. Today, RLV successfully bridges the gap between RDT&E and commercialization through its seasoned team. RLV staff possess decades of experience in new technology development and commercialization, aerospace and defense RDT&E, new company formation, financing, licensing, and mergers and acquisitions. We have the knowledge and ability to take you from now to wow.
Phillip Jeffries Ltd is a family-run company that specializes in the manufacture and importation of high-quality, unique, and textured wallcoverings. Founded in 1976 by Eric Bershad, the company has established itself as a global leader in the industry, offering an extensive range of over 1,000 natural wallcoverings. Their product lineup includes Japanese paper weaves, gold leaf, grasscloth, silks, and unique hand-crafted specialties, all crafted by skilled artisans to ensure exceptional quality and aesthetic appeal. The company is led by Eric Bershads sons, Philip and Jeffrey Bershad, who serve as President and Chief Executive Officer, respectively. This family involvement helps maintain the companys mission and values. Phillip Jeffries is known for its commitment to fast delivery, making it a preferred choice for interior designers, architects, and high-end homeowners seeking distinctive wallcovering solutions.